Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III adjuvant HER2-positive operable breast cancer trial comparing AC->T, AC->TH, and TCH
2008-005127-29Phase 3Completed
- Sponsor
- Sanofi
- Start
- Mar 2009
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trastuzumab, docetaxel, doxorubicin, cyclophosphamide and carboplatin in breast cancer (3 arms), sponsored by Sanofi. Primary endpoint: disease-free survival. Started Mar 2009; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2008-005127-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005127-29.